Urinary excretion of the main metabolites of 3,4-methylenedioxymethamphetamine (MDMA), including the sulfate and glucuronide of 4-hydroxy-3-methoxymethamphetamine (HMMA), in humans and rats

References

• Cole JC, Sumnal HR. Altered states: the clinical effects of ecstasy. Pharmacology and Therapeutics 2003; 98: 35–58
   PubMed Web of Science ®Google Scholar
• De la Torre R, Farre M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, Cami J. Human pharmacology of MDMA: pharmacokinetics, metabolism and disposition. Therapeutic Drug Monitoring 2004; 26: 137–144
   PubMed Web of Science ®Google Scholar
• Delaforge M, Jaouen M, Bouille G. Inhibitory metabolite complex formation of methylenedioxymethamphetamine with rat and human cytochrome P450. Particular involvement of CYP2D. Environmental Toxicology and Pharmacology 1999; 7: 153–158
   PubMed Web of Science ®Google Scholar
• Dumont GJ, Verkes RJ. A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers. Journal of Psychopharmacology 2006; 20: 176–187
   PubMed Web of Science ®Google Scholar
• Gentili S, Cornetta M, Macchia T. Rapid screening procedure based on headspace solid-phase microextraction and gas chromatography-mass spectrometry for the detection of many recreational drugs in hair. Journal of Chromatography B 2004; 801: 289–296
   PubMed Web of Science ®Google Scholar
• Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MS. The pharmacology and clinical pharmacology of 3,4-(methylenedioxy)methamphetamine (MDMA, ‘Ecstasy’). Pharmacological Reviews 2003; 55: 463–508
   PubMed Web of Science ®Google Scholar
• Han E, Park Y, Yang W, Lee J, Lee S, Kim E, Lim M, Chung H. The study of metabolite-to-parent drug ratios of methamphetamine and methylenedioxymethamphetamine in hair. Forensic Science International 2006; 161: 124–129
   PubMedGoogle Scholar
• Han E, Yang W, Lee J, Park Y, Kim E, Lim M, Chung H. The prevalence of MDMA/MDA in both hair and urine in drug users. Forensic Science International 2005; 152: 73–77
   PubMedGoogle Scholar
• Hemlin HJ, Bracher K, Bourquin D, Vonlanthen D, Brenneisen R. Analysis of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS. Journal of Analytical Toxicology 1996; 20: 432–440
   PubMedGoogle Scholar
• Kamata T, Nishikawa M, Katagi M, Tsuchihashi H. Optimized glucuronide hydrolysis for the detection of psilocin in human urine samples. Journal of Chromatography B 2003; 796: 421–427
   PubMed Web of Science ®Google Scholar
• Klette KL, Jamerson MH, Morris-Kukoski CL, Kettle AR, Suyder JJ. Rapid simultaneous determination of amphetamine, methamphetamine, 3,4-methylenedioxyamphetamine, 3,4-methylenedioxymethamphetamine, and 3,4-methylenedioxyethylamphetamine in urine by fast gas chromatography-mass spectrometry. Journal of Analytical Toxicology 2005; 29: 669–674
   PubMedGoogle Scholar
• Kreth K, Kovar K, Schwab M, Zanger U. Identification of the human cytochrome P450 involved in the oxidative metabolism of ‘ecstasy’ related designer drugs. Biochemical Pharmacology 2000; 59: 1563–1571
   PubMed Web of Science ®Google Scholar
• Lim HK, Foltz RL. In vivo and in vitro metabolism of 3,4-(methylenedioxy)methamphetamine in the rat: identification of metabolites using an ion trap detector. Chemical Research in Toxicology 1988; 1: 370–378
   PubMed Web of Science ®Google Scholar
• Lim HK, Foltz RL. Identification of metabolites of 3,4-(methylenedioxy)methamphetamine in human urine. Chemical Research in Toxicology 1989; 2: 142–143
   PubMedGoogle Scholar
• Lim HK, Foltz RL. In vivo formation of aromatic hydroxylated metabolites of 3,4-(methylenedioxy)methamphetamine in the rat: identification by ion trap tandem mass spectrometric (MS/MS and MS/MS/MS) techniques. Biological Mass Spectrometry 1991a; 20: 677–686
   PubMedGoogle Scholar
• Lim HK, Foltz RL. Ion trap tandem mass spectrometric evidence for the metabolism of 3,4-(methylenedioxy)methamphetamine to the potent neurotoxins 2,4,5-trihydroxymethamphetamine and 2,4,5-trihydroxyamphetamine. Chemical Research in Toxicology 1991b; 4: 626–632
   PubMedGoogle Scholar
• Lim HK, Zeng S, Chei DM, Foltz RL. Comparative investigation of disposition of 3,4-(methylenedioxy)methamphetamine (MDMA) in the rat and the mouse by a capillary gas chromatography-mass spectrometry assay based on perfluorotributylamine-enhanced ammonia positive ion chemical ionization. Journal of Pharmaceutical Biomedical and Analysis 1992; 10: 657–665
   PubMed Web of Science ®Google Scholar
• Lin LY, Stefano DI, Schmitz DA, Hsu L, Ellis SW, Lennard MS, Tucker GT, Cho AK. Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metabolism and Disposition 1997; 25: 1059–1064
   PubMed Web of Science ®Google Scholar
• Maurer HH, Bickeboeller-Friedrich J, Kraemer T, Peters FT. Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs (‘Ecstasy’). Toxicology Letters 2000; 112–113: 133–142
   PubMed Web of Science ®Google Scholar
• Müller CP, Carey RJ, Huston JP, De Souza Silva MA. Serotonin and psychostimulant addiction: focus on 5-HT1A-receptors. Progress in Neurobiology 2007; 81: 133–178
   PubMed Web of Science ®Google Scholar
• Nichols DE. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. Journal of Psychoactive Drugs 1986; 18: 305–313
   PubMed Web of Science ®Google Scholar
• Ortuño J, Pizarro N, Farré M, Mas M, Segura J, Camí J, Brenneisen R, De la Torre R. Quantification of 3,4-methylenedioxymethamphetamine and its metabolites in plasma and urine by gas chromatography with nitrogen–phosphorus detection. Journal of Chromatography B 1999; 723: 221–232
   PubMedGoogle Scholar
• Parrott AC. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress. Journal of Psychopharmacology 2006; 20: 147–163
   PubMed Web of Science ®Google Scholar
• Pirnay SO, Abraham TT, Lowe RH, Huestis MA. Selection and optimization of hydrolysis conditions for the quantification of urinary metabolites of MDMA. Journal of Analytical Toxicology 2006; 30: 563–569
   PubMedGoogle Scholar
• Pujadas M, Pichini S, Poudevida S, Menoyo E, Zuccaro P, Farre M, De la Torre R. Development and validation of a gas chromatography-mass spectrometry assay for hair analysis of amphetamine, methamphetamine and methylenedioxy derivatives. Journal of Chromatography B 2003; 798: 249–255
   PubMed Web of Science ®Google Scholar
• Salzmann J, Marie-Claire C, Noble F. Acute and long-term effects of ecstasy. Presse Medicale 2004; 33: 24–32
   PubMed Web of Science ®Google Scholar
• Segura M, Ortuño J, Farré M, McLure JA, Pujadas M, Pizarro N, Llebaria A, Joglar J, Roset PN, Segura J, De la Torre R. 3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. Chemical Research in Toxicology 2001; 14: 1203–1208
   PubMed Web of Science ®Google Scholar
• Shima N, Kamata HT, Katagi M, Tsichihashi H. Urinary excretion of the main metabolites of methamphetamine, including p-hydroxymethamphetamine-sulfate and p-hydroxymethamphetamine-glucuronide, in humans and rats. Xenobiotica 2006; 36: 259–267
   PubMed Web of Science ®Google Scholar
• Shima N, Kamata HT, Katagi M, Tsuchihashi H, Sakuma T, Nemoto N. Direct determination of glucuronide and sulfate of 4-hydroxy-3-methoxymethamphetamine, the main metabolite of MDMA, in human urine. Journal of Chromatography B 2007; 857: 123–129
   PubMedGoogle Scholar
• Shima N, Tsutsumi H, Katagi M, Tsichihashi H. Excretion of the sulfate and glucuronide of 4-hydroxy-3-methoxymethamphetamine (HMMA), the main urinary metabolite of MDMA, and their hydrolysis conditions. Japanese Journal of Forensic Toxicology 2005; 23: 124–125
   Google Scholar
• Shulgin A, Shulgin A. TiHKAL: the communication. Transform, Berkeley, CA 1997; 714–719–733–739
   Google Scholar
• Skrinska VA, Gock SB. Measurement of 3,4-MDMA and related amines in diagnostic and forensic laboratories. Clinical Laboratory Science 2005; 18: 119–123
   PubMedGoogle Scholar
• Stout P, Horn C, Klette L. Rapid simultaneous determination of amphetamine, methamphetamine, 3,4-methylenedioxyamphetamine, 3,4-methylenedioxymethamphetamine, and 3,4-methylenedioxyethylamphetamine in urine by solid-phase extraction and GC-MS: a method optimized for high-volume laboratories. Journal of Analytical Toxicology 2002; 26: 253–261
   PubMedGoogle Scholar
• Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, Hiratsuka A, Schmitz DA, Chu TYY. The demethylenation of methylenedioxymethamphetamine (‘ecstasy’) by desbrisoquine hydroxylase (CYP2D6). Biochemical Pharmacology 1994; 47: 1151–1156
   PubMed Web of Science ®Google Scholar
• Wu D, Otton SV, Inaba T, Kalow W, Sellers EM. Interactions of amphetamine analogs with human liver CYP2D6. Biochemical Pharmacology 1997; 53: 1605–1612
   PubMed Web of Science ®Google Scholar
• Yeh SY, Krebs HA, Gorodetzky CW. Isolation and identification of morphine N-oxide alpha- and beta-dihydromorphines, beta- or gamma-isomorphine, and hydroxylated morphine as morphine metabolites in several mammalian species. Journal of Pharmaceutical Science 1979; 68: 133–140
   PubMed Web of Science ®Google Scholar